Sugi Predict

Sugi Predict / Compounds / SCHEMBL17544378

SCHEMBL17544378

SCHEMBL17544378

C=CCOc1ccc(COc2ccc3oc(-c4ccc(=O)n(C)n4)nc3c2)nc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 4/20 0.39
▸ CA1 P00915 4/20 0.39
▸ CA9 Q16790 4/20 0.39
▸ ALDH1A1 P00352 2/20 0.37
▸ HPGD P15428 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ GPR119 Q8TDV5 1/20 0.36
▸ F2RL3 Q96RI0 4/20 0.34
▸ APP P05067 2/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ PDE10A Q9Y233 1/20 0.32
▸ AGER Q15109 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ AGPAT2 O15120 1/20 0.31
▸ HRH3 Q9Y5N1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30402899 1.00 CA12 (0.39) CA12CA1CA9ALDH1A1HPGD
SCHEMBL30400765 0.88 F2RL3 (0.41) ALDH1A1HPGDF2RL3APPHSD17B10
SCHEMBL17544475 0.88 F2RL3 (0.41) ALDH1A1HPGDF2RL3APPHSD17B10
SCHEMBL22393462 0.88 F2RL3 (0.41) CA12CA1CA9ALDH1A1HPGD
SCHEMBL17544312 0.86 HSD17B10 (0.36) CA12CA1CA9ALDH1A1HPGD
SCHEMBL29681127 0.86 HSD17B10 (0.36) CA12CA1CA9ALDH1A1HPGD
SCHEMBL22371531 0.84 NCF1 (0.38) F2RL3APPHRH3
SCHEMBL22371585 0.82 APP (0.35) F2RL3APPHRH3
SCHEMBL22371526 0.80 NCF1 (0.34) CA12CA9F2RL3APPMAPT
SCHEMBL22371571 0.79 GPR119 (0.34) ALDH1A1GPR119F2RL3APPKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258355-B2 Probes for imaging huntingtin protein CHDI FOUNDATION, INC. (US) 2025-03-25 — — US disclosed
US-12083108-B2 Compounds for targeting mutant huntingtin protein and uses thereof CHDI FOUNDATION, INC. (US) 2024-09-10 — — US disclosed
CN-116655618-A Probes for imaging huntingtin CHDI基金会股份有限公司 2023-08-29 — — CN disclosed
US-20230212190-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. 2023-07-06 — — US disclosed
US-20230212190-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. 2023-07-06 — — US disclosed
US-20230212190-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. 2023-07-06 — — US disclosed
CN-107108534-B Probes for imaging huntingtin CHDI基金会股份有限公司 2023-05-09 — — CN disclosed
US-20220409600-A1 COMPOUNDS FOR TARGETING MUTANT HUNTINGTIN PROTEIN AND USES THEREOF CHDI FOUNDATION, INC. 2022-12-29 — — US disclosed
US-20220409600-A1 COMPOUNDS FOR TARGETING MUTANT HUNTINGTIN PROTEIN AND USES THEREOF CHDI FOUNDATION, INC. 2022-12-29 — — US disclosed
US-11389438-B2 Compounds for targeting mutant huntingtin protein and uses thereof CHDI FOUNDATION, INC. (US) 2022-07-19 — — US disclosed
US-11059836-B2 Probes for imaging huntingtin protein CHDI FOUNDATION, INC. (US) 2021-07-13 — — US disclosed
US-20200276176-A1 COMPOUNDS FOR TARGETING MUTANT HUNTINGTIN PROTEIN AND USES THEREOF CHDI FOUNDATION, INC. 2020-09-03 — — US disclosed
US-20200102328-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN EVOTEC (UK) LTD. (GB) 2020-04-02 — — US disclosed
US-10479802-B2 Probes for imaging huntingtin protein CHDI FOUNDATION, INC. (US) 2019-11-19 — — US disclosed
US-10479802-B2 Probes for imaging huntingtin protein CHDI FOUNDATION, INC. (US) 2019-11-19 — — US disclosed
US-20170283436-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN EVOTEC (UK) LTD. (GB) 2017-10-05 — — US disclosed
US-20170283436-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN EVOTEC (UK) LTD. (GB) 2017-10-05 — — US disclosed
US-20170283436-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN EVOTEC (UK) LTD. (GB) 2017-10-05 — — US disclosed
EP-3186233-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI Foundation, Inc. (US) 2017-07-05 — — EP disclosed
WO-2016033445-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. (US) 2016-03-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212190-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN HTT, HYPK, HSPBP1 CA12 2572/4885CA1 941/4885CA9 3467/4885
US-12083108-B2 Compounds for targeting mutant huntingtin protein and uses thereof HTT, HYPK, UBQLN2 CA12 4715/4885CA1 4473/4885CA9 4824/4885
US-11389438-B2 Compounds for targeting mutant huntingtin protein and uses thereof HTT, HYPK, UBQLN2 CA12 4715/4885CA1 4473/4885CA9 4824/4885
US-20200276176-A1 COMPOUNDS FOR TARGETING MUTANT HUNTINGTIN PROTEIN AND USES THEREOF HTT, HYPK, UBQLN2 CA12 4715/4885CA1 4473/4885CA9 4824/4885
US-10479802-B2 Probes for imaging huntingtin protein HTT, HYPK, FABP7 CA12 2169/4885CA1 902/4885CA9 3202/4885
US-20220409600-A1 COMPOUNDS FOR TARGETING MUTANT HUNTINGTIN PROTEIN AND USES THEREOF HTT, HYPK, UBQLN2 CA12 4715/4885CA1 4473/4885CA9 4824/4885
US-11059836-B2 Probes for imaging huntingtin protein HTT, HYPK, HSPBP1 CA12 2572/4885CA1 941/4885CA9 3467/4885
US-20200102328-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN HTT, HYPK, HSPBP1 CA12 2572/4885CA1 941/4885CA9 3467/4885
US-20170283436-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN HTT, HYPK, FABP7 CA12 2169/4885CA1 902/4885CA9 3202/4885
US-12258355-B2 Probes for imaging huntingtin protein HTT, HYPK, HSPBP1 CA12 2572/4885CA1 941/4885CA9 3467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.